Advanced in Multiple Sclerosis (MS)

William Camu

Montpellier, FR 
Advanced in Multiple Sclerosis (MS)
Montpellier, FR 
OverviewLocationsClinical Research

Overview

William Camu practices in Montpellier, France. Mr. Camu is rated as an Advanced expert by MediFind in the treatment of Multiple Sclerosis (MS). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Multiple Sclerosis (MS), Andermann Syndrome, and Gastrostomy.

His clinical research consists of co-authoring 111 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 20 articles and participated in 2 clinical trials in the study of Multiple Sclerosis (MS).

Gender
Male

Locations

Montpellier, France
Other Locations
Roussillon-en-morvan, France
Tours, France
34295, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drugs: Riluzole, IL-2
Study Phase: Phase 2
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Vitamin D, Lumbar Puncture, Blood Sampling, Urine Samples
Study Phase: Phase 3
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial
Enrollment Status: Terminated
Publish Date: August 24, 2023
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 3
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Drug
Study Phase: Phase 3
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Unknown
Publish Date: July 10, 2023
Intervention Type: Drug
Study Drug: Tauroursodexycholic Acid
Study Phase: Phase 3
A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Drug
Study Drug: Teriflunomide
Study Phase: Phase 3
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS
Evaluation of Metabolomic Analysis in Early Diagnosis of ALS
Enrollment Status: Completed
Publish Date: July 17, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 6 Less Clinical Trials

111 Total Publications

Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes.
Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes.
Journal: BMJ case reports
Published: August 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Camu's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile